MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Gemcitabine (Gemzar)

Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma

Medical Oncology 2015 February [Link] de Lima VA, Sorensen JB. Abstract There is no well-defined standard third-line chemotherapy for advanced malignant pleural mesothelioma (MPM). However, combination of carboplatin, liposomised doxorubicin (Caelyx) and gemcitabine (CCG regimen) has revealed noteworthy activity when used as first-line treatment. The aim of this study is to assess efficacy and toxicity […]

Comments Off on Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma

Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study

Medical Oncology 2014 August. [Epub 2014 June 24] [Link] Akca Z, Buyukcelik A, Cihan YB, Coskun HS, Erden A, Gunduz S, Karaca H, Mutlu H. Abstract In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. […]

Comments Off on Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study

A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.

Cancer Chemotherapy Pharmacology. 2014 April 1.[Epub ahead of print][Link] Arrieta O, Bacon-Fonseca L, Blake-Cerda M, Corona-Cruz J.F., Lopez-Macias D, Macedo-Perez E.O., Mendoza-Garcia V.O., Muniz-Hernandez S, Munoz-Montano W Abstract PURPOSE: Low-dose, prolonged infusion of gemcitabine has effects similar to standard doses in several cancers. We evaluated the toxicity and efficacy of low-dose gemcitabine in prolonged infusion […]

Comments Off on A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.

Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients

Respiratory Investigation. 2014 March[

Comments Off on Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study

Journal of Occupational Medicine and Toxicology. 2008 Dec 18;3:34. [Link] Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. Respiratory Diseases Clinic Heckeshorn, Department of Pneumology, HELIOS Klinikum Emil von Behring, Berlin, Germany. torsten.bauer@helios-kliniken.de. Abstract Background: The aim of this study was to investigate the efficacy and safety of oxaliplatin +/- gemcitabine […]

Comments Off on Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

Cancer Immunology, Immunotherapy. 2009 Aug;58(8):1219-28. Epub 2008 Dec 4. [Link] van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. robbertvdm@gmail.com Abstract Tumor cell death potentially engages with the immune […]

Comments Off on Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia

Lung Cancer. 2009 Jun;64(3):308-13. Epub 2008 Nov 11. [Link] Lee CW, Murray N, Anderson H, Rao SC, Bishop W. BC Cancer Agency – Fraser Valley Centre, 13750 96th Avenue, Surrey, British Columbia, Canada V3V 1Z2. clee@bccancer.bc.ca Abstract Cisplatin plus pemetrexed has been standard systemic therapy for malignant pleural mesothelioma (MPM) since the landmark randomized trial […]

Comments Off on Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia

Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study

Journal of Thoracic Oncology. 2008 Nov;3(11):1325-31. [Link] Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Department of Lung Medicine and Allergology, Karolinska University Hospital, Solna, Stockholm, Sweden. gunnar.hillerdal@karolinska.se Abstract Background: Malignant pleural mesothelioma has a poor prognosis and there is limited effect of treatment. The Nordic Mesothelioma groups decided in the […]

Comments Off on Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study

Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

Journal of the Egyptian National Cancer Institute. 2007 Mar;19(1):61-70. [Link] Ryad AY, Mostafa E, Salem DA, Al-Adwy ER, Margerges M. The Departments of Radiation Oncology&Nuclear Medicine, Ain Shams University. Abstract Purpose: To evaluate the efficacy, safety, and clinical benefit of combined gemcitabine and carboplatin in patients with previously untreated malignant pleural mesothelioma (MPM). Patients and […]

Comments Off on Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Therapeutics and Clinical Risk Management. 2008 Jun;4(3):579-85. [Link] Felip E, Rosell R. Vall d’Hebron University Hospital Barcelona, Spain. Abstract NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with […]

Comments Off on Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)